Primary Care Today

What did the first day of the American Society of Nephrology’s Kidney Week 2021 showcase? From COVID-19 to developments in kidney disease, Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine, shares highlights from Day 1.

Kidney Week 2021 tackled everything from kidney transplants to systemic inequities. Here to share his insight on the latest updates is Dr. John Friedewald, Professor of Medicine and Surgery at the Northwestern University Feinberg School of Medicine.

What is cultural humility, and how can it be incorporated into clinical practice? How does your patient's culture impact their health behaviors, and why does your culture matter?

Listen in as two leading experts navigate concerns surrounding cultural humility and emphasize the importance of empathy, awareness, and advocacy. Discover ways to integrate small but important changes into your clinical practice to help bridge communication gaps and enable your patients to thrive.

Regional healthcare disparities are biases that are based on where people live. Are your patients’ treatment options being impacted and limited by their geographical location? Join us as our two experts discuss how to support broader policy issues and highlight the importance of diagnostic algorithms that have been developed with diverse input. These steps may be of value in your clinical practice to ensure all patients have equal access to care regardless of their epidemiologic, socioeconomic, or insurance circumstances.

Learn why diversity in clinical trials is so important to community health. Two experts discuss the key role that trusted messengers play in enrollment, why it is critical to break the cycle of medical mistrust, and the downstream effect of a lack of diversity in clinical trials.

Diversifying our physician workforce so that it is more racially, ethnically, and geographically balanced can ultimately have a positive impact on community health. Join us as two experts discuss how pipeline programs reaching children as early as elementary school can help ensure workplace diversity. Also find out how clinicians can be advocates for their patients by helping to disentangle them from structural inequities and working towards policy changes. There’s a lot than can be done to provide more balanced care, but we need to look beyond simple fixes to the root causes of the issues. So find your bandwidth – that’s what you can do today – and discover why it’s so important to move upstream to solve the problems manifesting downstream.

Armed with Centers for Disease Control and Prevention (CDC) guidelines for HCV universal screening and risk-based testing — and an understanding of the simplicity of prescribing and managing direct-acting antiviral (DAA) therapies — primary care providers (PCPs) will be well equipped to step up and provide comprehensive HCV care and cure. This educational activity offers practical tips and tactics to prepare PCPs for their central role in eliminating HCV.

Immune thrombocytopenia (ITP) is a heterogeneous disease characterized by unpredictable rates and severities of bleeding events, which complicate both its diagnosis and management. To help us overcome common challenges in ITP, Dr. James Bussel and Dr. Ralph Boccia join us to provide an overview of ITP, the diagnostic steps they recommend, and important treatment considerations through the care continuum.

©2020 Amgen Inc. All rights reserved. USA-531-80580 12/20

What’s the difference between a generic drug and biosimilar? How does the FDA define biosimilarity? And how are biosimilars developed? Get answers to these and other questions with Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC, in the first episode of this two-part video.

©2020 Amgen Inc. All rights reserved. USA-CBU-80726 10/20

Biosimilars undergo a rigorous evaluation process to ensure high quality and no clinically meaningful difference between biosimilars and the reference product. To learn more about how biosimilar clinical trials are designed to confirm biosimilarity, tune in to the second episode of this two-part series featuring Dr. Gary Cohen, Associate Professor of Oncology at John’s Hopkins School of Medicine and Emeritus Director of the Sandra and Malcolm Berman Cancer Institute at GBMC.

©2020 Amgen Inc. All rights reserved. USA-CBU-80729 10/20